Ionis Pharmaceuticals: Pioneering the Future of Medicine
Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
Sign Up for News Alerts
For the latest on Ionis news and developments
DAWNZERA showed sustained HAE attack rate reduction and long-term safety over two years 71% HAE attack rate reduction maintained after two years on DAWNZERA compared to baseline for patients switching from another long-term prophylactic therapy Treatment effect maintained regardless of dosing
CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 10, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference on Monday, November 16, 2026 Jefferies Global Healthcare
– ZANVASTRO ™ (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline – – TRYNGOLZA ® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).